Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Doxylamine succinate + ibuprofen is a combination of two small molecule drugs. Doxylamine succinate is an ethanolamine-derivative antihistamine with pronounced sedative and anticholinergic properties, commonly used as a short-term sleep aid and for relief of allergy or cold symptoms. It acts primarily as a histamine H1 receptor antagonist, blocking the action of histamine in the body to reduce allergic symptoms and induce sedation. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, leading to decreased synthesis of prostaglandins involved in pain, inflammation, and fever. The combination may be used off-label for symptomatic relief where both analgesia/anti-inflammatory effects (from ibuprofen) and sedative/antihistaminic effects (from doxylamine) are desired[5][6][7]. There are no known significant interactions between these two drugs when taken together[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on doxylamine succinate + ibuprofen.